Xeris Biopharma (XERS) Expected to Announce Quarterly Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Xeris Biopharma to announce earnings of $0.02 per share and revenue of $90.1250 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Stock Up 0.6%

Shares of Xeris Biopharma stock opened at $8.13 on Tuesday. The business has a 50-day moving average price of $7.55 and a 200 day moving average price of $6.78. Xeris Biopharma has a fifty-two week low of $5.25 and a fifty-two week high of $10.08. The firm has a market cap of $1.40 billion, a P/E ratio of 135.50 and a beta of 0.66. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Insider Buying and Selling

In other news, insider Steven Pieper sold 27,600 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00. Following the completion of the transaction, the insider directly owned 1,366,053 shares of the company’s stock, valued at approximately $11,638,771.56. This represents a 1.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dawn Halkuff sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $121,800.00. Following the completion of the sale, the director directly owned 95,000 shares in the company, valued at approximately $578,550. This trade represents a 17.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 234,833 shares of company stock valued at $1,742,622 over the last 90 days. 4.35% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of XERS. Cetera Investment Advisers grew its holdings in Xeris Biopharma by 3.9% during the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after acquiring an additional 1,735 shares during the period. Royal Bank of Canada lifted its holdings in Xeris Biopharma by 6.5% in the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after acquiring an additional 2,351 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in Xeris Biopharma in the 4th quarter valued at about $25,000. The Manufacturers Life Insurance Company boosted its position in shares of Xeris Biopharma by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 54,472 shares of the company’s stock valued at $254,000 after purchasing an additional 3,562 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.